Assembly Bio scraps hepatitis B drug, cuts staff after clinical setback

Assembly Biosciences is reorganizing and giving up on its lead drug after studies suggested the experimental medicine failed to significantly benefit hepatitis B patients when administered as part of a triple combination therapy.